Search Results
OlympiA: adjuvant olaparib following chemo significantly improves IDFS
OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancer
Perspectives on the OlympiA study of adjuvant olaparib in early breast cancer | Nadine Tung
Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer wit...
Breast Cancer Breakthrough - Prof Andrew Tutt on the OlympiA trial
ASCO 2021 - Highlights on shifting PARPi to Early Breast Cancer: The OlympiA study
Adjuvant Therapy | 2023 Best of Breast Conference
Updates in Extended Endocrine Therapy for HR+ Breast Cancer | ASCO21 & National Practice Guidelines
PARP Inhibitor Staves Off Recurrence in Early BRCA-Mutant Breast Cancer - Medpage Today
Educational Sessions: "PARP for BRCA+ breast cancers"
SOLO3 Reviews Potential Toxicities With Olaparib in Ovarian Cancer
BRCA-Positive Early-stage Breast Cancer: Treatment and Testing
